Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

RSS icon

FDA approves new medication for type 2 diabetes

The newly approved SGLT2 inhibitor, bexagliflozin, is marketed under the name Brenzavvy. It is not recommended for patients with type 1 diabetes. 

Peter Libby, MD, a cardiovascular medicine specialist, Brigham and Women’s Hospital, and Mallinckrodt Professor of Medicine, Harvard Medical School, explains the take aways from the PROMINENT trial using pemafibrate to lower cardiovascular risks. The trial, presented at the American Heart Association (AHA) 2022 meeting, did not show reduction in the incidence of cardiovascular events among those who received pemafibrate than among those who received placebo. #AHA #AHA22

VIDEO: Pemafibrate does not lower cardiovascular risks in the PROMINENT trial

Peter Libby, MD, a cardiovascular medicine specialist with Brigham and Women’s Hospital and Harvard Medical School, explained some key takeaways from the PROMINENT trial.

hospital ward

How cardiologists can improve in-hospital outcomes after PCI

Researchers evaluated if two recently developed risk scores can anticipate adverse in-hospital outcomes after PCI, sharing their findings in the American Journal of Cardiology.

PCI

A new antiplatelet strategy for treating diabetic PCI patients

Clopidogrel monotherapy after just one month of DAPT was associated with promising outcomes, including a reduction in bleeding events.

Peter Libby, MD, a cardiovascular medicine specialist, Brigham and Women’s Hospital, and Mallinckrodt Professor of Medicine, Harvard Medical School, explains his research into COVID and how damages the endothelium on blood vessels. #AHA #AHA22 #SARSCoV2 #Coronavirus #COVID

VIDEO: Why does COVID-19 damage vascular beds?

Peter Libby, MD, a cardiovascular medicine specialist at Brigham and Women’s Hospital, explains his research into COVID-19 and how it damages the endothelium of blood vessels. 

Thumbnail

AI specialists ink deal with Pfizer to target cardiac amyloidosis

Cardiac amyloidosis can be especially challenging to identify and diagnose, making it a perfect target for advanced AI models.

Thumbnail

No antithrombotic therapy after TAVR? New research highlights potential benefits

The study, published in JACC: Cardiovascular Interventions, focused on data from more than 3,500 TAVR patients. 

Thumbnail

World’s leading cardiology groups say it is time to rethink RCTs

The American College of Cardiology, American Heart Association, European Society of Cardiology and World Heart Federation all collaborated on a joint statement aimed at updating the rules and regulations associated with randomized clinical trials

Displaying 153 - 160 of 290

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup